Erin R Cleveland1, Hongyan Ning2, Miriam B Vos3, Cora E Lewis4, Mary E Rinella1, John Jeffrey Carr5, Donald M Lloyd-Jones2,6, Lisa B VanWagner7,8. 1. Department of Medicine-Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 1400, Chicago, IL, 60611, USA. 2. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. 3. Department of Pediatrics-Division of Gastroenterology, Hepatology & Nutrition, Emory University, Atlanta, GA, 30322, USA. 4. Department of Medicine-Division of Preventive Medicine, University of Alabama Birmingham, Birmingham, AL, 35294, USA. 5. Department of Radiology, Vanderbilt University, Nashville, TN, 37235, USA. 6. Department of Medicine-Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. 7. Department of Medicine-Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 1400, Chicago, IL, 60611, USA. lvw@northwestern.edu. 8. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. lvw@northwestern.edu.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, yet little is known about NAFLD awareness in individuals with incidental fatty liver on imaging. OBJECTIVE: To assess the level of awareness of imaging-defined NAFLD among individuals with and without metabolic risk factors. DESIGN: Cross-sectional analysis within a prospective longitudinal population-based cohort study conducted in four U.S. cities. PARTICIPANTS: Adults age 43 to 55 years enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study who underwent computed tomography and a personal health questionnaire at the year 25 exam (2010-2011, n = 2788). MAIN MEASURES: NAFLD was defined as liver attenuation ≤ 51 Hounsfield units after exclusion of other causes of liver fat. Participants were considered "NAFLD aware" if they reported being told previously by a doctor or nurse that they had "fatty liver." KEY RESULTS: NAFLD prevalence was 23.9%. Only 16 of 667 (2.4%) participants with CT-defined NAFLD were aware of a NAFLD diagnosis. NAFLD aware participants were more likely to be white (81.3% vs. 53.5%, p = 0.03) and have the metabolic syndrome (87.5% vs. 59.3%, p = 0.02) and/or hypertension (75.0% vs. 50.2%, p = 0.05). In multivariable analyses adjusted for demographics, metabolic syndrome and hypertension remained predictive of NAFLD awareness. CONCLUSION: There is low awareness of NAFLD among individuals with hepatic steatosis on imaging, even among those with metabolic risk factors. These findings highlight an opportunity to raise public and practitioner awareness of NAFLD with the goal of increasing diagnosis and implementing early treatment strategies.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, yet little is known about NAFLD awareness in individuals with incidental fatty liver on imaging. OBJECTIVE: To assess the level of awareness of imaging-defined NAFLD among individuals with and without metabolic risk factors. DESIGN: Cross-sectional analysis within a prospective longitudinal population-based cohort study conducted in four U.S. cities. PARTICIPANTS: Adults age 43 to 55 years enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study who underwent computed tomography and a personal health questionnaire at the year 25 exam (2010-2011, n = 2788). MAIN MEASURES: NAFLD was defined as liver attenuation ≤ 51 Hounsfield units after exclusion of other causes of liver fat. Participants were considered "NAFLD aware" if they reported being told previously by a doctor or nurse that they had "fatty liver." KEY RESULTS: NAFLD prevalence was 23.9%. Only 16 of 667 (2.4%) participants with CT-defined NAFLD were aware of a NAFLD diagnosis. NAFLD aware participants were more likely to be white (81.3% vs. 53.5%, p = 0.03) and have the metabolic syndrome (87.5% vs. 59.3%, p = 0.02) and/or hypertension (75.0% vs. 50.2%, p = 0.05). In multivariable analyses adjusted for demographics, metabolic syndrome and hypertension remained predictive of NAFLD awareness. CONCLUSION: There is low awareness of NAFLD among individuals with hepatic steatosis on imaging, even among those with metabolic risk factors. These findings highlight an opportunity to raise public and practitioner awareness of NAFLD with the goal of increasing diagnosis and implementing early treatment strategies.
Authors: Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant Journal: Arterioscler Thromb Vasc Biol Date: 2004-02 Impact factor: 8.311
Authors: Zobair M Younossi; Maria Stepanova; Brian Lam; Rebecca Cable; Sean Felix; Thomas Jeffers; Elena Younossi; Huong Pham; Manirath Srishord; Patrick Austin; Michael Estep; Kathy Terra; Carey Escheik; Leyla de Avila; Pegah Golabi; Andrej Kolacevski; Andrei Racila; Linda Henry; Lynn Gerber Journal: Hepatol Commun Date: 2021-07-21
Authors: Andrew D Schreiner; Jingwen Zhang; Valerie Durkalski-Mauldin; Sherry Livingston; Justin Marsden; John Bian; Patrick D Mauldin; William P Moran; Don C Rockey Journal: Diabetes Metab Res Rev Date: 2021-04-09 Impact factor: 4.876
Authors: Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan Journal: J Clin Transl Hepatol Date: 2021-10-22
Authors: Andrew D Schreiner; William P Moran; Jingwen Zhang; Sherry Livingston; Justin Marsden; Patrick D Mauldin; David Koch; Mulugeta Gebregziabher Journal: J Gen Intern Med Date: 2022-01-19 Impact factor: 6.473
Authors: Carolin V Schneider; Kai Markus Schneider; Donna M Conlon; Joseph Park; Marijana Vujkovic; Inuk Zandvakili; Yi-An Ko; Christian Trautwein; Regerneron Center; Rotonya M Carr; Pavel Strnad; Christoph A Thaiss; Daniel J Rader Journal: Med (N Y) Date: 2021-07-09
Authors: Andrew D Schreiner; Sherry Livingston; Jingwen Zhang; Mulugeta Gebregziabher; Justin Marsden; David G Koch; Chelsey A Petz; Valerie L Durkalski-Mauldin; Patrick D Mauldin; William P Moran Journal: J Clin Gastroenterol Date: 2021-07-22 Impact factor: 3.062